Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Shares Gap Up on Strong Earnings

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY)’s stock price gapped up before the market opened on Monday after the company announced better than expected quarterly earnings. The stock had previously closed at $9.04, but opened at $9.70. Shionogi & Co., Ltd. Unsponsored ADR shares last traded at $9.70, with a volume of 8,568 shares.

The company reported $0.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.18 by $0.18. Shionogi & Co., Ltd. Unsponsored ADR had a return on equity of 13.56% and a net margin of 41.08%.

Wall Street Analyst Weigh In

SGIOY has been the topic of a number of research analyst reports. Jefferies Financial Group raised shares of Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 14th. Zacks Research upgraded shares of Shionogi & Co., Ltd. Unsponsored ADR from a “strong sell” rating to a “hold” rating in a report on Monday, May 25th. Finally, The Goldman Sachs Group raised shares of Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research note on Monday, June 15th. Two investment analysts have rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Buy”.

Shionogi & Co., Ltd. Unsponsored ADR Trading Up 7.3%

The business has a 50 day simple moving average of $8.82 and a two-hundred day simple moving average of $9.88. The company has a current ratio of 1.58, a quick ratio of 1.46 and a debt-to-equity ratio of 0.01. The company has a market cap of $16.51 billion, a PE ratio of 12.13, a price-to-earnings-growth ratio of 3.55 and a beta of 0.09.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.

The company’s product portfolio spans both established and innovative therapies.